PDCD1 and non-small cell lung carcinoma: GSK3359609 is currently being evaluated in phase 2/3, in combination with pembrolizumab, in HNSCC patients with PD-L1-positive scores (INDUCE-3, NCT04128696), whereas JTX-2011 (vopratelimab) is currently being evaluated in a phase 2 study in combination with the anti–PD-1 monoclonal antibody JTX-4014 in patients with NSCLC who have not received immunotherapy (SELECT, NCT04549025).